Carl Kraus

Carl Kraus, M.D., FACP, currently serves as Chief Medical Officer at Aquestive Therapeutics since June 2023, following a role as Chief Medical Officer at Aceragen from November 2021 to April 2023. Previously, Carl held the position of Founder and Chief Executive Officer at Arrevus from January 2017 to October 2021 and was Chief Medical Officer at Nanotherapeutics, Inc. from February 2013 to January 2017. Additional experience includes serving as Vice President of Medical Affairs at Medscape/WebMD and Vice President of Scientific Affairs at both PRA International and i3, a UnitedHealth Group Company. Carl also worked as a Medical Officer at the Center for Drug Evaluation and Research at the US Food and Drug Administration and had a clinical associate role at the National Institute of Allergy and Infectious Diseases, NIH. Carl completed a Medical Degree at Washington University School of Medicine in St. Louis and holds a Bachelor of Arts in Biology from Washington University in St. Louis.